GHK-Cu FAQ: common questions answered

A copper-binding skin peptide with small topical studies and untested systemic injections.

Also called: Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper, Copper-GHK.

Healing and repair peptides · Copper-binding tripeptide complex.

  • Is GHK-Cu FDA-approved? No. PCAC consultation intended by February 2027; no completed decision found. No final 503A or 503B bulks-list inclusion confirmed. Cosmetics and medicine approval are separate.
  • How do people take it? Under the skin, once daily. User planned to stop after 8–12 weeks. Source: reported by users, not an established dose.
  • What's the difference between GHK-Cu and BPC-157? GHK-Cu: a copper-binding skin peptide with small topical studies and untested systemic injections. BPC-157: an experimental repair peptide with mostly animal evidence and a few small human reports. Why people pair them: reported with GHK-Cu for injury recovery and skin changes in recovery blends.
  • Can I take it with BPC-157? Reported with GHK-Cu for injury recovery and skin changes in recovery blends. No controlled human combination trial; mixed-vial stability and ingredient identity are unverified. Source: reported by users. Ask a doctor before combining anything.
  • Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). GHK-Cu is not named. S0 covers pharmacological substances without therapeutic approval; confirm cosmetic use with the anti-doping authority.
  • How long does a mixed vial last? Community reports refrigerate mixed vials. No validated GHK-Cu sterile beyond-use period was found.

Related to GHK-Cu

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.